Assessment of type I interferon response in routine practice in France in 2022

Eric Hachulla; Isabelle Melki; Brigitte Bader-Meunier; Alexandre Belot; Sophie Georgin-Lavialle; Sébastien Viel; Thierry Walzer; Anais Nombel; Anne Perrine Foray; Lorna Garnier; Christine Lombard

doi:10.1136/rmdopen-2023-003211

RMD Open (Apr 2023)

Assessment of type I interferon response in routine practice in France in 2022

Eric Hachulla,
Isabelle Melki,
Brigitte Bader-Meunier,
Alexandre Belot,
Sophie Georgin-Lavialle,
Sébastien Viel,
Thierry Walzer,
Anais Nombel,
Anne Perrine Foray,
Lorna Garnier,
Christine Lombard

Affiliations

Eric Hachulla: Département de Médecine Interne et d`Immunologie Clinique, Centre National de Référence Maladies Systémiques et Auto-immunes Rares Nord et Nord-Ouest de France (CeRAINO), European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNECT), Université de Lille, CHU Lille, Lille, France
Isabelle Melki: General Paediatrics, Department of Infectious Disease and Internal Medicine, Reference center for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Robert Debré Mother-Child University Hospital, AP-HP, Paris, France
Brigitte Bader-Meunier: Department of Paediatric Hematology-Immunology and Rheumatology, Reference center for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Necker-Enfants Malades Hospital, AP-HP, Paris, France
Alexandre Belot: International Center of Infectiology Research (CIRI), INSERM U1111, CNRS, UMR5308, ENS of Lyon, Claude Bernard University Lyon 1, Lyon, France
Sophie Georgin-Lavialle: Service Médecine Interne, Centre de référence des maladies autoinflammatoires et des amyloses (CEREMAIA), Hôpital Tenon, AP-HP, Paris, France
Sébastien Viel: Immunology Laboratory, Hôpital Lyon-Sud, Hospices Civils de Lyon, Lyon, France
Thierry Walzer: International Center of Infectiology Research (CIRI), INSERM U1111, CNRS, UMR5308, ENS of Lyon, Claude Bernard University Lyon 1, Lyon, France
Anais Nombel: Immunology Laboratory, Hôpital Lyon-Sud, Hospices Civils de Lyon, Lyon, France
Anne Perrine Foray: Immunology Laboratory, Hôpital Lyon-Sud, Hospices Civils de Lyon, Lyon, France
Lorna Garnier: Immunology Laboratory, Hôpital Lyon-Sud, Hospices Civils de Lyon, Lyon, France
Christine Lombard: Immunology Laboratory, Hôpital Lyon-Sud, Hospices Civils de Lyon, Lyon, France

DOI: https://doi.org/10.1136/rmdopen-2023-003211
Journal volume & issue: Vol. 9, no. 2

Abstract

Read online

An European Alliance of Associations for Rheumatology task force recently recommended specific points to consider for exploring type I interferon pathway in patients, highlighting the lack of analytical assays validated for clinical routine. We report here the French experience on a type I interferon pathway assay that has been set up and used routinely since 2018 in Lyon, France.

Published in RMD Open

ISSN: 2056-5933 (Online)
Publisher: BMJ Publishing Group
Country of publisher: United Kingdom
LCC subjects: Medicine
Website: https://rmdopen.bmj.com

About the journal